MedTrace Logo

A Novel Functional Imaging Technique With FLT-PET/MRI For Staging, Response Assessment and Radiation Treatment Planning in Cervix Cancer

NCT05355558 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-05-02

No results posted yet for this study

Summary

This pilot study aims to monitor early tumour response based on \[18F\]FLT-PET/MRI scans and to determine the feasibility of personalised radiotherapy to spare active bone marrow areas identified by \[18F\]FLT-PET/MRI. Bone marrow within the pelvis will be outlined by employing 18FLT PET to identify active BM within bony structures. Subsequently, treatment plans with various conformal radiotherapy techniques will be generated with different optimization approaches toward bone marrow while ensuring adequate tumor coverage.

Dosimetric comparison amongst plans will be carried out.

Conditions

  • Image, Body
  • Cervix Cancer

Interventions

DIAGNOSTIC_TEST

[18F]FLT-PET/MRI body scan

\[18F\]FLT-PET/MRI body scan will be done at * Visit 2 (Baseline-Pre-Treatment FLT-PET/MRI) which will occur between 1 to 28 days prior to initiation of radiotherapy. * Visit 3 (During Treatment FLT-PET/MRI) which will occur between week 4 to week 5 of External Beam Radiotherapy (before brachytherapy). At these visits: * Obtain vital signs and weight in kg before FLT administration. * Record the dose of FLT received and injected. (\*\*specify dose: 1mCi per 10kg. Maximum injected dose: \< 10mCi per patient.) * Place one (1) IV catheters into the participant's arm vein to inject the bolus of FLT. * Perform a saline flush following the FLT injection. * Body PET/MRI will be performed after FLT injection. * Time of injection of FLT and time of scan will need to be recorded.

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05355558 on ClinicalTrials.gov